Hematologic Malignancy
Acute Leukemia
CI-CAN-00000399Explore in graph →
Hematologic1,259 active trials30 approved drugs323 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000399Explore in graph →
Clinical trials
4,653 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (718)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01773395 | GVAX vs. Placebo for MDS/AML After Allo HSCT | terminated | Phase 2 | 123 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 18, 2022 | clinicaltrials |
| NCT01640301 | Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant | terminated | Phase 1 / Phase 2 | 47 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 14, 2022 |
| clinicaltrials |
| NCT00961142 | Haploidentical Stem Cell Transplantation With CD3/CD19 Depletion and Reduced Intensity Conditioning in Patients With Acute Leukemia(CD3/CD19 Haplo) | terminated | Phase 2 | 23 | University Hospital TuebingenOTHER | 1 | Jul 5, 2022 | clinicaltrials |
| NCT04093505 | Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia)(GnG) | terminated | Phase 3 | 28 | University Hospital HeidelbergOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT01177540 | Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects | terminated | Phase 2 | 25 | Eisai Inc.INDUSTRY | 3 | Jun 28, 2022 | clinicaltrials |
| NCT04326439 | AflacLL1901 (CHOA-AML) | terminated | Phase 2 | 8 | Emory UniversityOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT03063203 | Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia | terminated | Phase 2 | 17 | Washington University School of MedicineOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT02999854 | Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer(HATCY) | terminated | Phase 3 | 63 | Kiadis PharmaINDUSTRY | 13 | May 24, 2022 | clinicaltrials |
| NCT03552029 | Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML) | terminated | Phase 1 | 10 | Daiichi SankyoINDUSTRY | 1 | May 20, 2022 | clinicaltrials |
| NCT04844086 | RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies | terminated | Phase 1 | 2 | Eden BioCell Ltd.INDUSTRY | 1 | May 18, 2022 | clinicaltrials |
| NCT02043587 | Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma | terminated | Phase 2 | 31 | University of California, San DiegoOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT00968864 | T-cell Depleted Alternative Donor Transplantation | terminated | Phase 2 | 53 | Wake Forest University Health SciencesOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT02927938 | Leukemia Stem Cell Detection in Acute Myeloid Leukemia | terminated | Phase 3 | 18 | Wake Forest University Health SciencesOTHER | 1 | Apr 21, 2022 | clinicaltrials |
| NCT03600909 | A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia | terminated | Phase 2 | 3 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 12, 2022 | clinicaltrials |
| NCT04858594 | Study of Periodontitis and Blood Stream Infection in AML Patients Receiving Chemotherapy | terminated | — | 3 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT03217838 | Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants. | terminated | Phase 1 | 50 | AstraZenecaINDUSTRY | 2 | Apr 5, 2022 | clinicaltrials |
| NCT01187810 | Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL | terminated | Phase 1 | 3 | South Plains Oncology ConsortiumNETWORK | 1 | Mar 31, 2022 | clinicaltrials |
| NCT01876953 | Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 20 | City of Hope Medical CenterOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT03668392 | Asparaginase Activity Monitoring (AAM) in Adult Patients With Acute Lymphoblastic Leukemia (ALL)(ALL2518) | terminated | Phase 2 | 7 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT03151408 | An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia | terminated | Phase 3 | 406 | Helsinn Healthcare SAINDUSTRY | 16 | Mar 10, 2022 | clinicaltrials |
| NCT03696537 | IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT | terminated | Phase 1 | 6 | Naoyuki G. Saito, M.D., Ph.D.OTHER | 1 | Mar 9, 2022 | clinicaltrials |
| NCT03922477 | A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia | terminated | Phase 1 | 13 | Hoffmann-La RocheINDUSTRY | 1 | Feb 21, 2022 | clinicaltrials |
| NCT04044560 | Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant(OZM-097) | terminated | Phase 2 | 8 | University of British ColumbiaOTHER | 1 | Feb 21, 2022 | clinicaltrials |
| NCT03761069 | Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias | terminated | Phase 1 | 33 | PTC TherapeuticsINDUSTRY | 1 | Feb 2, 2022 | clinicaltrials |
| NCT03951961 | Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation | terminated | Phase 2 | 1 | University of JenaOTHER | 1 | Jan 21, 2022 | clinicaltrials |
| NCT04097301 | Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma | terminated | Phase 1 / Phase 2 | 8 | AGC Biologics S.p.A.INDUSTRY | 2 | Jan 19, 2022 | clinicaltrials |
| NCT03797261 | A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies | terminated | Phase 1 | 9 | AbbVieINDUSTRY | 3 | Dec 7, 2021 | clinicaltrials |
| NCT03557970 | JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 2 | 3 | OHSU Knight Cancer InstituteOTHER | 1 | Dec 2, 2021 | clinicaltrials |
| NCT03519984 | EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia | terminated | Phase 1 | 3 | University of Southern CaliforniaOTHER | 1 | Nov 30, 2021 | clinicaltrials |
| NCT02795520 | Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia | terminated | Phase 1 / Phase 2 | 32 | OncoTherapy Science, Inc.INDUSTRY | 1 | Nov 24, 2021 | clinicaltrials |
| NCT01620216 | Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia | terminated | Phase 2 | 12 | OHSU Knight Cancer InstituteOTHER | 1 | Nov 4, 2021 | clinicaltrials |
| NCT02770820 | Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 9 | Fred Hutchinson Cancer CenterOTHER | 1 | Oct 29, 2021 | clinicaltrials |
| NCT04051996 | GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia | terminated | Phase 2 | 1 | Yale UniversityOTHER | 1 | Oct 15, 2021 | clinicaltrials |
| NCT00766779 | HCT Versus CT in Elderly AML | terminated | Phase 3 | 126 | European Society for Blood and Marrow TransplantationNETWORK | 7 | Oct 14, 2021 | clinicaltrials |
| NCT02319369 | Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) | terminated | Phase 1 | 74 | Daiichi SankyoINDUSTRY | 1 | Oct 11, 2021 | clinicaltrials |
| NCT03588936 | Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant | terminated | Phase 1 | 2 | Medical College of WisconsinOTHER | 1 | Oct 11, 2021 | clinicaltrials |
| NCT02298166 | Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations | terminated | Phase 3 | 9 | University of UlmOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT03473457 | CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia(AML) | terminated | N/A | 2 | Zhujiang HospitalOTHER | 1 | Sep 13, 2021 | clinicaltrials |
| NCT01439347 | A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL | terminated | Phase 3 | 26 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Sep 9, 2021 | clinicaltrials |
| NCT03742323 | REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia | terminated | Phase 1 / Phase 2 | 6 | PETHEMA FoundationOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT02105116 | AML Therapy With Irradiated Allogeneic Cells | terminated | N/A | 6 | Rutgers, The State University of New JerseyOTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT02229266 | Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AML(HINKL) | terminated | Phase 2 | 1 | Technische Universität DresdenOTHER | 1 | Aug 16, 2021 | clinicaltrials |
| NCT01113502 | Eltrombopag in Elderly Acute Myelogenous Leukemia (AML) | terminated | Phase 1 / Phase 2 | 44 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT02440568 | AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients | terminated | Phase 1 / Phase 2 | 22 | University of Illinois at ChicagoOTHER | 1 | Jul 6, 2021 | clinicaltrials |
| NCT01486784 | A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia | terminated | Phase 1 / Phase 2 | 27 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 24, 2021 | clinicaltrials |
| NCT03806192 | Feasibility of Partners in Care Program for Caregivers of Patients With Acute Myeloid Leukemia | terminated | N/A | 12 | University of WashingtonOTHER | 1 | Jun 23, 2021 | clinicaltrials |
| NCT00914628 | Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia(TK008) | terminated | Phase 3 | 92 | AGC Biologics S.p.A.INDUSTRY | 10 | Jun 22, 2021 | clinicaltrials |
| NCT00967343 | Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor | terminated | Phase 2 / Phase 3 | 40 | Kiadis PharmaINDUSTRY | 7 | Jun 14, 2021 | clinicaltrials |
| NCT03579888 | CD19-Specific T Cells Post AlloSCT | terminated | Phase 1 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 2, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Jul 18, 2022source: clinicaltrials